Truist raised the firm’s price target on Biogen (BIIB) to $190 from $142 and keeps a Hold rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $225 from $197 at Goldman Sachs
- Biogen price target raised to $207 from $177 at Mizuho
- Biogen: Buy Rating Raised on Leqembi Commercial Momentum and 2026 Pipeline Catalysts
- Biogen: Balanced Risk/Reward Amid Alzheimer’s and Autoimmune Pipeline Uncertainty Supports Hold Rating
- Biogen price target raised to $180 from $153 at Citi